The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Christopher R Zito; Lucia B Jilaveanu; Valsamo Anagnostou; David Rimm; Gerold Bepler; Sauveur-Michel Maira; Wolfgang Hackl; Robert Camp; Harriet M Kluger; Herta H Chao (Profiled Author: Gerold Bepler)
Yale University School of Medicine & Yale Comprehensive Cancer, New Haven, Connecticut, United States of America.
PloS one 2012;7(2):e31331.
INTRODUCTION: We assessed expression of p85 and p110α PI3K subunits in non-small cell lung cancer (NSCLC) specimens and the association with mTOR expression, and studied effects of targeting the PI3K/AKT/mTOR pathway in NSCLC cell lines. METHODS: Using Automated Quantitative Analysis we quantified expression of PI3K subunits in two cohorts of 190 and 168 NSCLC specimens and correlated it with mTOR expression. We studied effects of two PI3K inhibitors, LY294002 and NVP-BKM120, alone and in combination with rapamycin in 6 NSCLC cell lines. We assessed activity of a dual PI3K/mTOR inhibitor, NVP-BEZ235 alone and with an EGFR inhibitor. RESULTS: p85 and p110α tend to be co-expressed (p<0.001); p85 expression was higher in adenocarcinomas than squamous cell carcinomas. High p85 expression was associated with advanced stage and poor survival. p110α expression correlated with mTOR (ρ = 0.276). In six NSCLC cell lines, addition of rapamycin to LY294002 or NVP-BKM120 was synergistic. Even very low rapamycin concentrations (1 nM) resulted in sensitization to PI3K inhibitors. NVP-BEZ235 was highly active in NSCLC cell lines with IC(50)s in the nanomolar range and resultant down-regulation of pAKT and pP70S6K. Adding Erlotinib to NVP-BEZ235 resulted in synergistic growth inhibition. CONCLUSIONS: The association between PI3K expression, advanced stage and survival in NSCLC suggests that it might be a valuable drug target. Concurrent inhibition of PI3K and mTOR is synergistic in vitro, and a dual PI3K/mTOR inhibitor was highly active. Adding EGFR inhibition resulted in further growth inhibition. Targeting the PI3K/AKT/mTOR pathway at multiple levels should be tested in clinical trials for NSCLC.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Dong-Jun Peng; Juan Wang; Jun-Ying Zhou; Gen Sheng WuBiochemical and biophysical research communications 2010;394(3):600-5.
Valsamo K Anagnostou; Anastasios T Dimou; Taxiarchis Botsis; Elizabeth J Killiam; Mark D Gustavson; Robert J Homer; Daniel Boffa; Vassiliki Zolota; Dimitrios Dougenis; Lynn Tanoue; et al.Cancer 2012;118(6):1607-18.
Merry Y Zhao; Aaron Auerbach; Anisha M D'Costa; Aaron P Rapoport; Angelika M Burger; Edward A Sausville; Sanford A Stass; Feng Jiang; Amy M Sands; Nadine Aguilera; et al.Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1708-20.
Appears in this Publication
Author of this Publication